Neutralization of SARS-CoV-2 Variants by rVSV-∆G-Spike-Elicited Human Sera

Yfat Yahalom-Ronen, Noam Erez, Morly Fisher, Hadas Tamir, Boaz Politi, Hagit Achdout, Sharon Melamed, Itai Glinert, Shay Weiss, Inbar Cohen-Gihon, Ofir Israeli, Marina Izak, Michal Mandelboim, Yoseph Caraco, Noa Madar-Balakirski, Adva Mechaly, Eilat Shinar, Ran Zichel, Daniel Cohen, Adi Beth-DinAnat Zvi, Hadar Marcus, Tomer Israely, Nir Paran

Research output: Contribution to journalArticlepeer-review


The emergence of rapidly spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a major challenge to the ability of vaccines and therapeutic antibodies to provide immunity. These variants contain mutations of specific amino acids that might impede vaccine efficacy. BriLife® (rVSV-∆G-spike) is a newly developed SARS-CoV-2 vaccine candidate currently in phase II clinical trials. It is based on a replication-competent vesicular stomatitis virus (VSV) platform. The rVSV-∆G-spike contains several spontaneously acquired spike mutations that correspond to SARS-CoV-2 variants’ mutations. We show that human sera from BriLife® vaccinees preserve comparable neutralization titers towards alpha, gamma, and delta variants and show less than a three-fold reduction in the neutralization capacity of beta and omicron compared to the original virus. Taken together, we show that human sera from BriLife® vaccinees overall maintain a neutralizing antibody response against all tested variants. We suggest that BriLife®-acquired mutations may prove advantageous against future SARS-CoV-2 VOCs.

Original languageEnglish
Article number291
Issue number2
StatePublished - Feb 2022


  • BriLife®
  • COVID-19
  • Convalescent
  • Neutralization
  • SARS-CoV-2
  • VOC
  • VSV
  • Vaccine
  • Variants


Dive into the research topics of 'Neutralization of SARS-CoV-2 Variants by rVSV-∆G-Spike-Elicited Human Sera'. Together they form a unique fingerprint.

Cite this